简介：ToaugmentspecificcytotoxicTlymphocyte(CTL)lysisisapromisingstrategyforcancertherapy.Inthisstudy,weexaminedtheboostingeffectofCTLsuponautologouslymphoblastoidBcelllines(LCLs)transfectedwithdiverseplasmids,toexplorethepossibleCTL-basedimmunotherapyofnasopharyngealcarcinoma(NPC).FCManalysisdisplayedratherhighratio(＞30%)ofsuccessfullytransfectedLCLsbyutilizingtheDMRIE-Ckit.CTLassaysdemonstratedthatsubstantiallyhigherratioofCTLspecificlysiswasobservedupontheLCLstransfectedwithbothexpressionvectorsencodingEBV-specificepitopesandtheirpresentationmoleculeHLA-A2,incontrastwiththosetransfectedseparately.BytransfectingthevectorencodingHLA-A2alone,onlytheLCLsofHLA-A2+donorselicitedmarkedlyhigherCTLlysis.CTLassaysalsoshowedthatthereexistednomarkeddifferencesupontransfectionbyeitherdifferentvectors(pcDNA3,pNGVL3orpNGVL3-hFlex),ordifferentEBV-derivedpeptides(LMP2Pep1orLMP2Pep2),orwithorwithoutthedoubledDNAsequenceencodingpeptides.ThisstudyindicatedapromisingimmunotherapystrategyonNPCthroughboostingandelicitingtheEBV-specificCTLactivationbytransferringvectorsencodingbothEBV-specificepitopesandtheirpresentationmoleculeHLA-A2intoautologousLCL,thepresentationcellsofMHC/peptidetetramericcomplex.
客服QQ：30444492琼网文【2021】1550-113号
增值电信业务经营许可证：琼B2-20210322
出版物经营许可证：新出发龙华出字第(2021)009号
广播电视节目制作经营许可证：(琼)字第00779号
版权所有 ©2002-2024 期刊网(www.qikanchina.com) 琼ICP备2021005105号
